Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:NTRP Neurotrope (NTRP) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisCompetitorsEarningsHeadlinesShort InterestTrends About Neurotrope Stock (NASDAQ:NTRP) 30 days 90 days 365 days Advanced Chart Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Get Neurotrope alerts:Sign Up Key Stats Today's Range$1.76▼$1.8750-Day Range$0.92▼$1.0552-Week Range$0.68▼$3.85Volume8,692 shsAverage Volume34,835 shsMarket Capitalization$2.66 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewNeurotrope, Inc., a biopharmaceutical company, focuses on the development of a product platform for the treatment of Alzheimer's disease. The company's lead product candidate is bryostatin, a natural product isolated from a marine invertebrate organism, a bryozoan called Bugula neritina. It also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, multiple sclerosis, and niemann-pick type C diseases. The company has a license agreement with The Board of Trustees of the Leland Stanford Junior University for the use of bryostatin structural derivatives, known as bryologs, for use in the treatment of central nervous system disorders, lysosomal storage diseases, stroke, cardio protection, and traumatic brain injury; and a license agreement to an accelerated synthesis of bryostatin-1. Neurotrope, Inc. also has a cooperative research and development agreement with the National Cancer Institute for the research and clinical development of Bryostatin-1. The company was founded in 2012 and is based in New York, New York.Read More… 625,000% Gain (Ad)Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Neurotrope Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks6th Percentile Overall ScoreNTRP MarketRank™: Neurotrope scored higher than 6% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Neurotrope. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Neurotrope are expected to grow in the coming year, from ($0.91) to ($0.10) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Neurotrope is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Neurotrope is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNeurotrope has a P/B Ratio of 0.56. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Neurotrope's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.91% of the float of Neurotrope has been sold short.Short Interest Ratio / Days to CoverNeurotrope has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Neurotrope has recently increased by 6.67%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNeurotrope does not currently pay a dividend.Dividend GrowthNeurotrope does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.91% of the float of Neurotrope has been sold short.Short Interest Ratio / Days to CoverNeurotrope has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Neurotrope has recently increased by 6.67%, indicating that investor sentiment is decreasing significantly. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Neurotrope this week, compared to 0 articles on an average week. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Neurotrope insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.70% of the stock of Neurotrope is held by insiders.Percentage Held by InstitutionsOnly 3.81% of the stock of Neurotrope is held by institutions.Read more about Neurotrope's insider trading history. Receive NTRP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neurotrope and its competitors with MarketBeat's FREE daily newsletter. Email Address NTRP Stock News HeadlinesNextTrip (NASDAQ:NTRP) Stock Quotes, Forecast and News SummaryOctober 6, 2024 | benzinga.comNextTrip, Inc.: NextTrip Introduces Group Booking Technology Platform to Streamline and Simplify Travel for GroupsAugust 2, 2024 | finanznachrichten.de625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.November 13, 2024 | Crypto Swap Profits (Ad)NextTrip, Inc. (NTRP) Stock Price, News, Quote & History - Yahoo FinanceMay 18, 2024 | finance.yahoo.comNextTrip, Inc. (NTRP) Latest Stock News & Headlines - Yahoo FinanceApril 30, 2024 | finance.yahoo.comNextTrip Inc NTRPApril 4, 2024 | morningstar.comAlzheimer's Disease Market Predicted to Surge at a CAGR of 20% During the Study Period (2019–2032), Assesses DelveInsightAugust 17, 2023 | finance.yahoo.comAt 6.9% CAGR, Global Erectile Dysfunction Drugs Market Size & Share Will Hit US$ 5.94 Billion | Industry Trends, Demand, Growth, Value, Analysis & Forecast Report by Zion Market Research - Yahoo FinanceJune 22, 2022 | finance.yahoo.comSee More Headlines NTRP Stock Analysis - Frequently Asked Questions How were Neurotrope's earnings last quarter? Neurotrope, Inc. (NASDAQ:NTRP) issued its quarterly earnings results on Tuesday, October, 30th. The company reported ($0.40) EPS for the quarter, topping analysts' consensus estimates of ($0.45) by $0.05. What other stocks do shareholders of Neurotrope own? Based on aggregate information from My MarketBeat watchlists, some other companies that Neurotrope investors own include Sarepta Therapeutics (SRPT), Neos Therapeutics (NEOS), Fibrocell Science (FCSC), Bristol-Myers Squibb (BMY), Intel (INTC), Meta Platforms (META) and Pfizer (PFE). Company Calendar Last Earnings10/30/2018Today11/12/2024Next Earnings (Estimated)1/21/2025Fiscal Year End2/28/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorConsumer Discretionary Industry Transportation services Sub-IndustryN/A Current SymbolNASDAQ:NTRP CUSIPN/A CIK1513856 Webwww.neurotropebioscience.com Phone973-242-0005Fax505-424-3174Employees5Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($10.97) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax Margin-905.46% Return on Equity-286.56% Return on Assets-100.34% Debt Debt-to-Equity RatioN/A Current Ratio0.27 Quick Ratio0.27 Sales & Book Value Annual Sales$630,000.00 Price / Sales3.83 Cash FlowN/A Price / Cash FlowN/A Book Value$3.34 per share Price / Book0.51Miscellaneous Outstanding Shares1,420,000Free Float1,283,000Market Cap$2.41 million OptionableNo Data Beta1.67 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report This page (NASDAQ:NTRP) was last updated on 11/13/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredYou just voted for a financial crisisI’d like to share with you my #1 high-conviction stock to buy before Inauguration Day… and details on the asse...Porter & Company | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neurotrope, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neurotrope With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.